
Johnson & Johnson beats Q2 earnings estimates and raises 2026 sales and EPS guidance.
Johnson & Johnson reported better-than-expected Q2 2026 results with adjusted EPS of $2.90, surpassing estimates, and revenue of $25.31 billion, driven by strong pharmaceutical sales. Key growth came from the Innovative Medicine segment, with notable...

